Osteoporosis in the at-risk asthmatic

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 11, 2014, Pages 1429-1439

  Aljubran, S A ^a   Whelan, G J ^a   Glaum, M C ^a   Lockey, R F ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

asthma; bisphosphonates; glucocorticoids; osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; MONTELUKAST; PREDNISONE; SALBUTAMOL; ANTIASTHMATIC AGENT; BONE DENSITY CONSERVATION AGENT; CORTICOSTEROID;

ADULT; ASTHMA; BONE DENSITY; BONE MASS; CASE REPORT; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DIET SUPPLEMENTATION; EXERCISE; FEMALE; HUMAN; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OSTEOPOROSIS; REVIEW; RISK; SYSTEMIC THERAPY; COMPLICATION; DRUG EFFECTS; FRACTURES, BONE; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIETARY SUPPLEMENTS; DIPHOSPHONATES; EXERCISE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK;

EID: 84907930482     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12438     Document Type: Review

References (64)

1. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004.
2. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL,. Perspective: how many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-1010.
3. Randell A, Sambrook PN, Nguyen TV, Lapsley H, Jones G, Kelly PJ, et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 1995; 5: 427-432.
4. Cooper C,. Epidemiology of osteoporosis. Osteoporos Int 1999; 9 (Suppl 2): S2-S8.
5. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375-382.
6. Melton LJ III, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL,. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999; 10: 214-221.
7. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010.
8. Alesci S, De Martino MU, Ilias I, Gold PW, Chrousos GP,. Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects. NeuroImmunoModulation 2005; 12: 1-19.
9. Wong CA, Walsh LJ, Smith CJ, Wisniewski AF, Lewis SA, Hubbard R, et al. Corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355: 1399-1403.
10. Tattersfield AE, Town GI, Johnell O, Picado C, Aubier M, Braillon P, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 2001; 56: 272-278.
11. Langhammer A, Forsmo S, Lilleeng S, Jonhsen R, Bjermer L,. Effect of inhaled corticosteroids on forearm bone mineral density: the HUNT Study, Norway. Respir Med 2007; 101: 1744-1752.
12. American Lung Association Trends in Asthma Mortality. American Lung Association Epidemiology & Statistics Unit Research and Program Services, May 2005.
13. CDC National Vital Statistics 2008, for 2006-FIND 2010.
14. Pasaoglu G, Gok H, Mungan D, Sonel B, Yalcin P, Misirligil Z,. Does the combination of inhaled steroids with long acting beta2 agonists decrease the risk for osteoporosis? A 1-year prospective follow-up study. Rheumatol Int 2006; 27: 141-146.
15. Theophilus A, Moore A, Prime D, Rossomanno S, Whitcher B, Chrystyn H,. Co-deposition of salmeterol and fluticasone propionate by a combination inhaler. Int J Pharm 2006; 313: 14-22.
16. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136: 1456-1465.
17. Elefteriou F,. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 2008; 473: 231-236.
18. Uusi-Rasi K, Sievanen H, Pasanen M, Oja P, Vuori I,. Association of physical activity and calcium intake with the maintenance of bone mass in premenopausal women. Osteoporos Int 2002; 13: 211-217.
19. Stewart KJ, Deregis JR, Turner KL, Bacher AC, Sung J, Hees PS, et al. Fitness, fatness and activity as predictors of bone mineral density in older persons. J Int Med 2002; 252: 381-388.
20. Kemmler W, Lauber D, Weineck J, Hensen J, Kalender W, Engelke K,. Benefits of 2 years of intense exercise on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women. Arch Intern Med 2004; 164: 1084-1091.
21. Benton MJ, White A,. Osteoporosis: recommendations for resistance exercise and supplementation with calcium and vitamin D to promote bone health. J Community Health Nurs 2006; 23: 201-211.
22. Englund U, Littbrand H, Sondell A, Bucht G, Pettersson U,. The beneficial effects of exercise on BMD are lost after cessation: a 5-year follow-up in older post-menopausal women. Scand J Med Sci Sports 2009; 19: 381-388.
23. Sutherland ER, Goleva E, Jackson LP, Stevens AD, Leung DY,. Vitamin D levels, lung function, and steroid response in adult asthma. Am J Respir Crit Care Med 2010; 181: 699-704.
24. Scopacasa F, Need AG, Horowitz M, Wishart JM, Morris HA, Nordin BE,. Effects of dose and timing of calcium supplementation on bone resorption in early menopausal women. Horm Metab Res 2002; 34: 44-47.
25. Wood RJ, Serfaty-Lacrosniere C,. Gastric acidity, atrophic gastritis, and calcium absorption. Nutr Rev 1992; 50: 33-40.
26. Straub DA,. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 2007; 22: 286-296.
27. Heller HJ, Stewart A, Haynes S, Pak CY,. Pharmacokinetics of calcium absorption from two commercial calcium supplements. J Clin Pharmacol 1999; 39: 1151-1154.
28. Hanzlik RP, Fowler SC, Fisher DH,. Relative bioavailability of calcium from calcium formate, calcium citrate, and calcium carbonate. J Pharmacol Exp Ther 2005; 313: 1217-1222.
29. Varenna M, Bertoldo F, Di Monaco M, Giusti A, Martini G, Rossini M, et al. Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo 2013; 65: 143-166.
30. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ,. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126: 497-504.
31. Taylor EN, Stampfer MJ, Curhan GC,. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15: 3225-3232.
32. Xiao Q, Murphy RA, Houston DK, Harris TB, Chow WH, Park Y,. Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP Diet and Health Study. JAMA Intern Med 2013; 173: 639-646.
33. Tannirandorn P, Epstein S,. Drug-induced bone loss. Osteoporos Int 2000; 11: 637-659.
34. Briot K, Roux C,. Drug-induced osteoporosis: beyond glucocorticoids. Curr Rheumatol Rep 2008; 10: 102-109.
35. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD,. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-326.
36. Yang YX, Lewis JD, Epstein S, Metz DC,. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953.
37. Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB,. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 2008; 123: 1733-1740.
38. Davignon J, Leiter LA,. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005; 1: 29-40.
39. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 2007; 92: 4671-4677.
40. Clevenbergh P, Corcostegui M, Gérard D, Hieronimus S, Mondain V, Chichmanian RM, et al. Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. J Infect 2002; 44: 194-195.
41. Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN,. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004; 38: 46-49.
42. Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA,. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90: 4394-4398.
43. Fleisch H,. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
44. Fleisch H,. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-34.
45. Lau EC, Woo J, Chan YH, Li M,. Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone 2001; 29: 506-510.
46. Herrala J, Puolijoki H, Liippo K, Raitio M, Impivaara O, Tala E, et al. Clodronate is effective in preventing corticosteroid-induced bone Loss among asthmatic patients. Bone 1998; 22: 577-582.
47. Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM,. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 2004; 59: 761-768.
48. Kasayama S, Fujita M, Goya K, Yamamoto H, Fujita K, Morimoto Y, et al. Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. Metab 2005; 54: 85-90.
49. Schilcher J, Michaëlsson K, Aspenberg P,. Bisphosphonate Use and Atypical Fractures of the Femoral Shaft. N Engl J Med 2011; 364: 1728-1737.
50. Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaëlsson K, Aspenberg P,. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 2013; 52: 389-392.
51. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783-789.
52. Filleul O, Crompot E, Saussez S,. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010; 136: 1117-1124.
53. Panzianas M, Abrahamsen B,. Safety of bisphosphonates. Bone 2011; 49: 103-110.
54. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V,. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444.
55. Lyles KW, Colõn-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. HORIZON recurrent fracture trial zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809.
56. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010; 62: 1515-1526.
57. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-2822.
58. Reginster JY, Malaise O, Neuprez A, Bruyere O,. Strontium ranelate in the prevention of osteoporotic fractures. Int J Clin Pract 2007; 61: 324-328.
59. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362: 686-696.
60. Kharode Y, Bodine P, Miller C, Lyttle CR, Komm BS,. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008; 149: 6084-6091.
61. Marjoribanks J, Farquhar C, Roberts H, Lethaby A,. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7: CD004143.
62. Whyte MP,. The long and the short of bone therapy. N Engl J Med 2006; 354: 860-863.
63. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010; 69: 872-875.
64. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-420.